IL2 and cancer: Furthermore, we stress that while IL-2 production can be boosted or restored by the systemic blockade of checkpoint inhibitors [76, 77], how production of IL-2 by T cells responding to respiratory infection impacts patient outcome in such settings, including cancer therapy, remains to be determined.